Medical Imaging Biochemical Markers Clinical Research Centers
About Synarc Synarc Experts News & Events
Confirming the potential of new agents in global neurology studies
 
 
Therapeutic Expertise
   Rheumatoid Arthritis

pdf iconNeurology arrow

 
brochure thumbnailDownload PDF brochure of Synarc services in Neurology.

Services in Neurology

 

Synarc is the world leader in centralized medical-imaging services for global multicenter studies of Alzheimer’s disease and other neurodegenerative diseases, including vascular dementia.

We provide a full range of imaging markers, as well as centralized, independent
confirmation of subject diagnoses prior to study commencement. In addition, we fully support all global sites, regardless of location. Our highly experienced neurology team is composed of neurologists, neuroradiologists, MRI physicists, image-analysis technicians, and program and project staff with extensive understanding of what it takes to succeed in a global neurology study. Let us bring our insights to your next endeavor.

Rigorous site qualification and training

Our thorough site-qualification procedures ensure that study sites have the staff, equipment, and support necessary to perform imaging protocols throughout the investigation. Synarc provides extensive, hands-on training in image acquisition and data transfer to help ensure the delivery of standardized, high-quality, and reproducible readings.

Rigorous and ongoing quality control

Image-acquisition quality control is maintained by continual verification of image quality, including absence of motion and other artifacts, appropriate contrast and resolution, phantom equipment monitoring, and monthly monitoring of quality-control metrics.

Specialized measurement of brain atrophy
in Alzheimer’s disease

Quantifying progressive brain atrophy is essential in identifying drugs that slow the rate of neurodegeneration of Alzheimer’s disease. Quantitative longitudinal measurements of the rate of brain atrophy using structural MRI are not affected by changes in brain function, and therefore provide specific measures of neurodegeneration and brain atrophy.

Exclusive regulatory compliance

Synarc neurology software is validated and meets FDA requirements for use in drug trials. It is the only 21 CFR Part 11 compliant system of its kind available for MRI analysis in Alzheimer’s disease trials. In addition, Web-based image transfer provides immediate delivery of images to Synarc from sites worldwide. Start here, finish first.

 
Medical Experts Medical Directors
spacer
pdf iconJoyce Suhy, Ph.D. image
Scientific Director, Neurology
 
pdf iconMichael W. Weiner, M.D. image
Scientific Expert, Alzheimer’s Disease and Dementia
image

brain scan

 

 
   © Copyright 2008 Synarc Inc.   Legal Statement